Payment overview · 2025
General Payments
$1,794.64
94 reported records · 23 companies
Healthcare provider profile · identity verified
Anson Hsieh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOWLING GREEN, KY · NPI 1316940596
Verified facts
What the public records show
CMS Open Payments records show Anson Hsieh, MD received $1,794.64 in general payments during 2025 across 94 reported records.
Novartis Pharmaceuticals Corporation accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Kerendia, Linzess, Otezla, Paxlovid, Prolia, Rexulti, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 478 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $275.85 | 15.4% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $248.16 | 13.8% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $201.76 | 11.2% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.15 | 8.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.84 | 7.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.70 | 7.7% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $123.30 | 6.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.44 | 5.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.31 | 4.3% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.60 | 2.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.56 | 2.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.66 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.73 | 1.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.90 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.22 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.04 | 1.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $18.34 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.30 | 1.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.94 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.80 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.22 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.13 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.69 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,794.64 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $275.85 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $213.65 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $201.76 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $144.15 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $123.30 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $97.23 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.76 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $83.54 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $83.54 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $77.31 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $62.96 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.56 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $45.08 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 318 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 478 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 207 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 17 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 117 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
207 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
478 | 70 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
318 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1368 | 255 |
| Losartan Potassium | Losartan Potassium | 839 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 774 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 772 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 639 | 121 |
| Sertraline Hcl | Sertraline Hcl | 584 | 89 |
| Furosemide | Furosemide | 569 | 115 |
| Omeprazole | Omeprazole | 543 | 103 |
| Gabapentin | Gabapentin | 512 | 84 |
| Jardiance | Empagliflozin | 478 | 70 |
| Lisinopril | Lisinopril | 452 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 449 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 437 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 406 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 393 | 85 |
| Trazodone Hcl | Trazodone Hcl | 375 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 373 | 74 |
| Montelukast Sodium | Montelukast Sodium | 370 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 367 | 70 |
| Potassium Chloride | Potassium Chloride | 330 | 64 |
| Prednisone | Prednisone | 328 | 190 |
| Metformin Hcl | Metformin Hcl | 325 | 65 |
| Eliquis | Apixaban | 318 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 94 |
| Buspirone Hcl | Buspirone Hcl | 266 | 49 |
| Meloxicam | Meloxicam | 265 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 41 |
| Ezetimibe | Ezetimibe | 253 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 248 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 232 | 38 |
| Famotidine | Famotidine | 227 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 221 | 50 |
| Baclofen | Baclofen | 212 | 46 |
| Linzess | Linaclotide | 207 | 35 |
| Carvedilol | Carvedilol | 174 | 43 |
| Olanzapine | Olanzapine | 171 | 24 |
| Januvia | Sitagliptin Phosphate | 169 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 29 |
| Bupropion Xl | Bupropion Hcl | 166 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 165 | 46 |
| Mirtazapine | Mirtazapine | 162 | 33 |
| Glimepiride | Glimepiride | 157 | 37 |
| Ozempic | Semaglutide | 157 | 29 |
| Celecoxib | Celecoxib | 156 | 31 |
| Donepezil Hcl | Donepezil Hcl | 150 | 28 |
| Spironolactone | Spironolactone | 150 | 39 |
| Sucralfate | Sucralfate | 147 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 24 |
| Memantine Hcl | Memantine Hcl | 145 | 24 |
| Allopurinol | Allopurinol | 144 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 144 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 33 |
| Ibuprofen | Ibuprofen | 143 | 45 |
| Finasteride | Finasteride | 134 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 134 | 56 |
| Promethazine Hcl | Promethazine Hcl | 134 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 131 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 124 | 24 |
| Naproxen | Naproxen | 123 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 22 |
| Tramadol Hcl | Tramadol Hcl | 118 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 117 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 116 | 21 |
| Ondansetron Odt | Ondansetron | 114 | 28 |
| Alendronate Sodium | Alendronate Sodium | 110 | 26 |
| Risperidone | Risperidone | 110 | 14 |
| Valsartan | Valsartan | 108 | 17 |
| Nabumetone | Nabumetone | 106 | 24 |
| Xarelto | Rivaroxaban | 103 | 14 |
| Levetiracetam | Levetiracetam | 102 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 21 |
| Alprazolam | Alprazolam | 98 | 16 |
| Farxiga | Dapagliflozin Propanediol | 97 | 25 |
| Simvastatin | Simvastatin | 97 | 24 |
| Nystatin | Nystatin | 96 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 93 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 90 | 16 |
| Cefuroxime | Cefuroxime Axetil | 89 | 62 |
| Minoxidil | Minoxidil | 88 | 15 |
| Vascepa | Icosapent Ethyl | 84 | 13 |
| Lansoprazole | Lansoprazole | 83 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 24 |
| Pregabalin | Pregabalin | 79 | 17 |
| Warfarin Sodium | Warfarin Sodium | 78 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 77 | 12 |
| Entresto | Sacubitril/Valsartan | 77 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 20 |
| Topiramate | Topiramate | 75 | 14 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 15 |
| Aripiprazole | Aripiprazole | 69 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 69 | 58 |
| Meclizine Hcl | Meclizine Hcl | 68 | 22 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 26 |
| Clonidine Hcl | Clonidine Hcl | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 21 |
| Nifedipine Er | Nifedipine | 62 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 43 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 12 |
| Bumetanide | Bumetanide | 59 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | suppressed |
| Irbesartan | Irbesartan | 58 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 57 | 11 |
| Novolog Flexpen | Insulin Aspart | 57 | suppressed |
| Fluconazole | Fluconazole | 55 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | suppressed |
| Lidocaine | Lidocaine | 53 | 15 |
| Lubiprostone | Lubiprostone | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 50 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Lactulose | Lactulose | 47 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 13 |
| Diazepam | Diazepam | 46 | suppressed |
| Estradiol | Estradiol | 46 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 16 |
| Azelastine Hcl | Azelastine Hcl | 44 | suppressed |
| Oxycontin | Oxycodone Hcl | 44 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 44 | suppressed |
| Lovastatin | Lovastatin | 43 | 11 |
| Amoxicillin | Amoxicillin | 42 | 38 |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 30 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Ssd | Silver Sulfadiazine | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 37 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Febuxostat | Febuxostat | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 31 |
| Kerendia | Finerenone | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Armour Thyroid | Thyroid,pork | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Cephalexin | Cephalexin | 30 | 22 |
| Desmopressin Acetate | Desmopressin Acetate | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 20 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Otezla | Apremilast | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | 17 |
| Midodrine Hcl | Midodrine Hcl | 28 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Metronidazole | Metronidazole | 26 | 17 |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Flunisolide | Flunisolide | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 11 |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Acetazolamide | Acetazolamide | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Primidone | Primidone | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Metolazone | Metolazone | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Famciclovir | Famciclovir | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Prolia | Denosumab | 17 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 16 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Insulin Aspart | Insulin Aspart | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Carafate | Sucralfate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Aripiprazole Odt | Aripiprazole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dupixent Pen | Dupilumab | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,794.64 · 94 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, CREON, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, NEXLETOL, NURTEC ODT, OTEZLA, PAXLOVID, PROLIA, QULIPTA, Quviviq, REPATHA, REXULTI, TRELEGY ELLIPTA, TZIELD, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error